Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment

Am J Dis Child. 1984 Apr;138(4):388-91. doi: 10.1001/archpedi.1984.02140420054017.


We evaluated the growth rate and pubertal status of 54 adolescent and young adult men with cystic fibrosis and assessed the efficacy of short-term androgen therapy in promoting growth and pubertal development. Thirty-nine percent were below the fifth percentile in height and 8/28 (28%) between the ages of 14 and 18 had delays in pubertal development. Five male adolescents aged 13 years 8 months to 18 years 3 months were treated with testosterone and their conditions were prospectively evaluated. Growth rate increased from an entry mean of 2.2 cm/yr (range 0 to 4 cm/yr) to 7.2 cm/yr (3 to 10 cm/yr). We conclude that a brief course of testosterone appears to be a safe, effective means of improving growth rate in male adolescents with cystic fibrosis with delay of puberty.

MeSH terms

  • Adolescent
  • Adult
  • Anthropometry
  • Body Height*
  • Child
  • Cystic Fibrosis / complications*
  • Evaluation Studies as Topic
  • Growth
  • Growth Disorders / drug therapy*
  • Humans
  • Male
  • Personality Inventory
  • Prospective Studies
  • Puberty, Delayed / drug therapy*
  • Puberty, Delayed / etiology
  • Puberty, Delayed / psychology
  • Retrospective Studies
  • Sex Factors
  • Testosterone / therapeutic use*


  • Testosterone